読み込み中
Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, neurology, and gastroenterology. Its current portfolio includes: Gvoke: A ready-to-administer liquid glucagon designed to treat severe hypoglycemia. Keveyis: A therapy addressing hyperkalemic, hypokalemic, and related forms of primary periodic paralysis. Recorlev: A cortisol synthesis inhibitor approved for managing endogenous hypercortisolemia in adult patients with Cushing's syndrome. Beyond its marketed products, the company maintains an active development pipeline. This pipeline seeks to broaden the applications and indications for existing treatments and introduce novel pharmaceuticals leveraging its proprietary XeriSol and XeriJect formulation technology platforms. Founded in 2005, Xeris Biopharma is headquartered in Chicago, Illinois.
通常取引
$10.4188
−$0.0612 · -0.58%
日中の時刻はETです。市場データは遅延する場合があります。
Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, neurology, and gastroenterology. Its current portfolio includes: Gvoke: A ready-to-administer liquid glucagon designed to treat severe hypoglycemia. Keveyis: A therapy addressing hyperkalemic, hypokalemic, and related forms of primary periodic paralysis. Recorlev: A cortisol synthesis inhibitor approved for managing endogenous hypercortisolemia in adult patients with Cushing's syndrome. Beyond its marketed products, the company maintains an active development pipeline. This pipeline seeks to broaden the applications and indications for existing treatments and introduce novel pharmaceuticals leveraging its proprietary XeriSol and XeriJect formulation technology platforms. Founded in 2005, Xeris Biopharma is headquartered in Chicago, Illinois.
日中レンジ
現在 $10.4188
52週レンジ
現在 $10.4188
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
買い
バリュエーション
87
大幅な割安
センチメント
50
まちまち
リスク
38
中程度のリスク
モメンタム
61
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, neurology, and gastroenterology. Its current portfolio includes: Gvoke: A ready-to-administer liquid glucagon designed to treat severe hypoglycemia. Keveyis: A therapy addressing hyperkalemic, hypokalemic, and related forms of primary periodic paralysis. Recorlev: A cortisol synthesis inhibitor approved for managing endogenous hypercortisolemia in adult patients with Cushing's syndrome. Beyond its marketed products, the company maintains an active development pipeline. This pipeline seeks to broaden the applications and indications for existing treatments and introduce novel pharmaceuticals leveraging its proprietary XeriSol and XeriJect formulation technology platforms. Founded in 2005, Xeris Biopharma is headquartered in Chicago, Illinois.
日中レンジ
現在 $10.4188
52週レンジ
現在 $10.4188
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 2.92億 USD | 2.03億 USD | 1.64億 USD | 1.1億 USD | 4959万 USD |
| 売上原価 | 5341.2万 USD | 3683.2万 USD | 2864.5万 USD | 2263.4万 USD | 1331.8万 USD |
| 粗利益 | 2.38億 USD | 1.66億 USD | 1.35億 USD | 8761.4万 USD | 3627.2万 USD |
| 研究開発 | 3116.5万 USD | 2556万 USD | 2234.1万 USD | 2096.6万 USD | 2516万 USD |
| 販売・一般管理 | 1.82億 USD | 1.63億 USD | 1.46億 USD | 1.38億 USD | 1.26億 USD |
| 営業費用 | 2.14億 USD | 2億 USD | 1.79億 USD | 1.7億 USD | 1.51億 USD |
| 受取利息 | 474.2万 USD | 532.1万 USD | 475.1万 USD | 257.8万 USD | 31.3万 USD |
| 支払利息 | 2908.4万 USD | 3317.5万 USD | 2660.9万 USD | 1410.2万 USD | 718万 USD |
| 減価償却費と償却費 | 1215.6万 USD | 1262.5万 USD | 1316万 USD | 1266.8万 USD | 187.9万 USD |
| 営業利益 | 2489.6万 USD | −3364.6万 USD | −4401万 USD | −8194万 USD | −1.15億 USD |
| 純利益 | 55.4万 USD | −5483.6万 USD | −6225.5万 USD | −9466万 USD | −1.23億 USD |
会社概要が更新されました 2026年10月12日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$15.00
上昇余地（43.97%）この株式へのエクスポージャーを報告している上場投資信託です。
iShares Russell 2000 ETFIWM4668.29万0.06%787.4億 USD0.19%$278.61-0.12%
Vanguard Morningstar Total Stock Market ETFVTI4383.45万0.00%2.3兆 USD0.03%$382.03+0.02%
Vanguard Extended Market ETFVXF1694.55万0.02%954億 USD0.05%$234.36-0.27%
iShares Russell 2000 Growth ETFIWO1651.43万0.12%139.17億 USD0.24%$354.86-0.54%
State Street SPDR S&P Pharmaceuticals ETFXPH1239.53万2.69%4.62億 USD0.35%$64.25-0.62%
Fidelity Enhanced Small Cap ETFFESM1128.97万0.17%64.1億 USD0.28%$45.40-0.13%
Schwab U.S. Small-Cap ETFSCHA989.65万0.05%218.24億 USD0.03%$32.775-0.05%
First Trust Small Cap Growth AlphaDEX FundFYC937.59万0.69%13.49億 USD0.70%$115.04-0.28%iShares Russell 2000 ETFIWMVanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOState Street SPDR S&P Pharmaceuticals ETFXPHFidelity Enhanced Small Cap ETFFESMSchwab U.S. Small-Cap ETFSCHAFirst Trust Small Cap Growth AlphaDEX FundFYCAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
